Significant biosimilar activities this week include 31 Jul 20 | US | Vizient has advised its member health groups to...
Pearce IP BioBlast™: w/e 07 August 2020
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast™: w/e 31 July 2020
Significant biosimilar activities this week include 27 Jul 20 | EU | Celltrion announced the European Commission has...
Pearce IP BioBlast™: w/e 24 July 2020
Significant biosimilar activities this week include 20 Jul 20 | EU | Spherix reported that the EU market for AbbVie's...
Pearce IP BioBlast™: w/e 17 July 2020
Significant biosimilar activities this week include 09 Jul 20 | AU | The Australian Generic and Biosimilar Medicines...
Pearce IP BioBlast™: w/e 10 July 2020
Significant biosimilar activities this week include 05 Jul 20 | In its 2019-2020 Annual Report, Biocon announced it...
USPTO Creates Program to Resolve Ex Parte Appeals in 6 Months
The United States Patent and Trademark Office (USPTO) announced a pilot program to fast track appeals to the Patent...
Pearce IP BioBlast™: w/e 03 July 2020
Significant biosimilar activities this week include 28 Jun 20 | US Genentech filed a complaint against Samsung...
New Thinking for New Science- Biopharmaceutical Patent Disputes in Australia
First published as: Naomi Pearce, Dr Jennifer Enmon and Kadri Elcoat, 'New Thinking for New Science -...
Pearce IP BioBlast™: w/e 26 Jun 2020
Significant biosimilar activities this week include June 20 | The NZ Herald reported a new study by NZ scientists...
IAM Patent 1000: Two Pearce IP patent leaders ranked among world’s best
Boutique specialist patent firm Pearce IP is proud to report a strong presence in the prestigious IAM Patent...
Pearce IP BioBlast™: w/e 12 Jun 2020
Significant biosimilar activities this week include 08 Jun 20 | The Centre for Biosimilars reported that the WHO...
Pearce IP BioBlast™: w/e 05 Jun 2020
Significant biosimilar activities this week include 29 May 20 | In a filing to the Securities and Exchange...
Pearce IP BioBlast™: w/e 29 May 2020
Significant biosimilar activities this week include 25 May 20 | The American Journal of Managed Care reported two cost...
Pearce IP promotes Jennifer Enmon PhD to Special Counsel
We are delighted to announce the promotion of Jennifer Enmon PhD from Senior Associate to Special Counsel. Jennifer...
Pearce IP BioBlast™: w/e 22 May 2020
Significant biosimilar activities this week include 11 May 20 | AstraZeneca announced it had recovered the global...
Pearce IP BioBlast™: w/e 15 May 2020
Significant biosimilar activities this week include 11 May 20 | Healio reported on a new study comparing faricimab to...